Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC).

摘要: 699Background: Cet, a monoclonal antibody against EGFR, is standard therapy for pts with RAS wild-type (WT) mCRC. Limited previous data suggest that Cet clearance correlates progression-free survival (PFS). We performed population pharmacokinetic (pop-pK) analysis of in who participated the randomized phase III NCIC CO.20 trial KRAS WT mCRC patients. Methods: Standard doses ± brivanib were administered. Using intermittent trough blood samples, pop-pK was conducted to evaluate different models. Pts divided into quartiles according parameters assess exposure-response relationship response rate (RR), PFS and overall (OS). Clinical variables including demographic, laboratory, disease characteristics co-administration evaluated as co-variates on clearance. Results: In 701 pts, elimination best described one-compartment model non-linear saturable process (defined by Vmax Km). Mea...